Pancreaticoduodenal resection with marginal resection of the portal vein: case study
DOI:
https://doi.org/10.18203/2349-2902.isj20233685Keywords:
Pancreatic head cancer, Portal vein, Superior mesenteric vein, Pancreatoduodenal resection, Gastropancreatoduodenal resection, HepaticojejunostomyAbstract
Pancreatic cancer (PC) represents a challenging manifestation of a gastrointestinal tumour, which poses a formidable impediment for healthcare professionals and patients alike. The prognosis for this condition is often discouraging, particularly following a pancreatectomy, which has a poor five-year survival rate. The sole practical cure for PC is surgical resection, despite the negative outcomes. The standard surgical procedure for pancreatic head cancer is pancreaticoduodenectomy (PD). Although PD has been associated with higher morbidity and mortality rates, recent advancements have reduced the risks associated with this operation. When it comes to PC surgery, one promising approach is the resection of the portal vein. This technique has been shown to improve the ability to remove the cancerous tissue (resectability) and to remove it completely (radicality). This study was carried out at the department of pancreatology hepatology and transplantation of organs and tissues, Grodno regional clinical hospital in Grodno, Belarus. Our team treated a patient with pancreatic adenocarcinoma, who underwent a pancreaticoduodenal resection and marginal resection of the portal vein as part of their treatment plan. PD with marginal resection of the portal vein reduces risks and improves patient outcomes, as confirmed by CT and ultrasound data. Further research is needed to expand its efficacy and improve patients' recovery and quality of life post-surgery.
References
Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019;10(1):10-27.
Clinical guidelines for the diagnosis and treatment of malignant tumours of the pancreas. Moscow, Russia, 2014;31-8.
Mostafa ME, Erbarut-Seven I, Pehlivanoglu B, Adsay V. Pathologic classification of ‘pancreatic cancers’: Current concepts and challenges. Chinese Clin Oncol. 2017;6(6):59.
Park W, Chawla A, O’Reilly EM. Pancreatic Cancer: A Review. J Am Med Asso. 2021;326(9):851-62.
O’Neill RS, Stoita A. Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket? World J Gastroenterol. 2021;27(26):4045-87.
Bachellier P, Nakano H, Oussoultzoglou PD, Weber JC, Boudjema K, Wolf PD et al. Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile? Am J Surg. 2001;182(2):120-9.
Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Sur. 2003;185(5):476-80.
Beger HG. Diseases of the Pancreas Current Surgical Therapy. Beger HG, Cameron JL edi. Berlin: Heidelberg. 2008;527-39.
Are C, Dhir M, Ravipati L. History of pancreaticoduodenectomy: Early misconceptions, initial milestones and the pioneers. HPB. 2011;13:377-84.
Buchs NC, Chilcott M, Poletti PA, Buhler LH, Morel P. Vascular invasion in pancreatic cancer: Imaging modalities, preoperative diagnosis and surgical management. World J Gastroenterol. 2010;16:818-31.
Vareedayah AA, Alkaade S, Taylor JR. Pancreatic Adenocarcinoma. Mo Med. 2018;115(3):230-35.
Puckett Y, Karen G. Pancreatic Cancer Continuing Education Activity. Treasure Island (FL): StatPearls Publishing. 2023.
Maitra A, Hruban RH. Pancreatic cancer. Mechanisms of Disease. Ann Rev Pathol. 2008;3:157-88.
Li HY, Cui ZM, Chen J, Guo XZ, Li YY. Pancreatic cancer: diagnosis and treatments. Tumor Biol. 2015;36(3):1375-84.
Coco D, Leanza S, Guerra F. Total Pancreatectomy: Indications, Advantages and Disadvantages - A Review. Maedica (Bucur). 2019;14:391-6.
Brown TJ, Reiss KA, O’Hara MH. Advancements in Systemic Therapy for Pancreatic Cancer. American Society of Clinical Oncology Educational Book. 2023;43:e397082.
